NextCure, Inc. — Director's Dealing 2019

May 9, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NextCure, Inc. (NXTC)
CIK: 0001661059
Period of Report: 2019-05-08

Reporting Person: Sofinnova Venture Partners IX, L.P. (10% Owner)
Reporting Person: Sofinnova Management IX, L.L.C. (10% Owner)
Reporting Person: HEALY JAMES (10% Owner)
Reporting Person: POWELL MICHAEL (10% Owner)
Reporting Person: Mehra Anand (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 Preferred Stock	$		Common Stock (278759)		Direct
Series A-2 Preferred Stock	$		Common Stock (464599)		Direct
Series A-3 Preferred Stock	$		Common Stock (908785)		Direct
Series B-1 Preferred Stock	$		Common Stock (469713)		Direct

Footnotes

F1: The reported securities are convertible into shares of Common Stock on a 1-for-8.0338 basis at the holder's election, will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering, and have no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.